Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
7,819,192
-
Total 13F shares
-
1,031,877
-
Share change
-
+54,041
-
Total reported value
-
$2,021,917
-
Price per share
-
$1.96
-
Number of holders
-
25
-
Value change
-
+$102,393
-
Number of buys
-
12
-
Number of sells
-
11
Institutional Holders of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) as of Q2 2024
As of 30 Jun 2024,
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,031,877 shares.
The largest 10 holders included
K2 PRINCIPAL FUND, L.P., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, EQUITEC PROPRIETARY MARKETS, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA SECURITIES, LLC, UBS Group AG, DIMENSIONAL FUND ADVISORS LP, and Schonfeld Strategic Advisors LLC.
This page lists
25
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.